News

Cystic Fibrosis Canada calls on remaining provinces to save lives and list Trikafta immediately

Cystic Fibrosis Canada applauds Ontario, Alberta, and Saskatchewan for listing Trikafta under public drug benefit programs 

Provinces pressed to save lives by following guidance from CF clinicians, and fund Trikafta now for all Canadians who can benefit

A letter has been sent to the Honourable François Legault, Premier of the Province of Quebec, and Christian Dubé, Minister of Health, regarding the INESSS recommendation for the cystic fibrosis drug, Trikafta. 

Cystic Fibrosis Canada calls on Quebec Health Minister to save lives by instead following the guidelines developed by CF clinicians, and fund Trikafta now for all Quebecers who can benefit...

Fundraising milestone a reflection of Kin Canada club members’ decades long commitment to the CF community.

 Cystic Fibrosis Canada has published new standardized care guidelines for modulator use in Canada.

If implemented, CADTH’s recommendation for the public funding of Trikafta would see access limited to only some of those who could benefit, requiring people to become sicker before offering treatment.

The Canadian Agency for Drugs and Technologies in Health (CADTH) provided this week short sighted and narrow guidance regarding game changing cystic fibrosis (CF) drug Trikafta, that, if adopted by the provinces, could effectively exclude over 25% of eligible Canadians with cystic fibrosis (CF), many of whom are youth, who could greatly benefit from the drug.

Cystic Fibrosis Canada is providing an exciting opportunity for the cystic fibrosis (CF) community to participate in a new study that will study the impact, both in time and money, that cystic fibrosis has on people living with the disease, their families and on society. Launched today, The Social and Economic Impact of Cystic Fibrosis in Canada: A Burden of Disease Study is open for registrations now until July 25, 2021.